terameprocol

Terameprocol is a synthetic tetra-methylated derivative of nordihydroguaiaretic acid (NDGA) and functions as a global transcription inhibitor with potential antiviral, antiangiogenic, and antineoplastic activities. It selectively inhibits specificity protein 1 (Sp1)-regulated proteins such as survivin (BIRC5), cyclin-dependent kinase 1 (Cdc2), and vascular endothelial growth factor (VEGF). By inhibiting Sp1-mediated transcription, terameprocol disrupts cell cycle progression, induces apoptosis in cancer cells by downregulating survivin expression and activation, and decreases angiogenesis. Preclinical studies have shown potent anticancer activity in tumor cell lines and animal models. Terameprocol has also demonstrated the ability to inhibit the proliferation of viruses including HIV, HSV, and HPV by deactivating viral Sp1-dependent promoters. The drug has been investigated primarily for brain tumors such as glioblastoma in phase I/II clinical trials[1][3][5][6][7].

Other names

meso-Tetra-O-methylnordihydroguaiaretic acidmeso-Tetramethoxy-4,4'-(2,3-dimethyltetramethylene)dipyrocatecholTetra-O-methyl nordihydroguaiaretic acidTetra-O-methyl-NDGATetramethoxynordihydroguaiaretic acid